* The FDA approved the registration of a new 55 ml Vitastem spray bottle. This came at the request of hospitals that have tested the product. A larger spray version will be easier to apply the medication to large wounds.
* Liberdol, a new relief pain product was officially launched in 2020. The analgesics market in the U.S. is estimated to be more than $12 billion dollars.
* An extended line of credit was secured for financing future manufacturing. We anticipate sales to top 500,000 units in 2021.
* A large national hospital chain and a major health insurance company have completed successful testing of the Vitastem product. We are now in the final stages of discussions to determine the size of the initial purchase.
* Successful product testing was completed by a major midwestern university with whom we are also in discussions regarding their initial product purchase.
* We have initiated discussions with a major global medical nonprofit that has expressed interest in purchasing Vitastem for use by their doctors and medical staff in treating patients.
—————————
a target projection of 500,000 units sold for 2021 was given. If reached, multiplying by $79/unit = $39.5 m in revenue x 50% margins) = 20m earnings. At 20x earnings (for this growth) = a 400m market cap/1B= $.40 share target
Vitastem – Powerful Super-Healing Topical Antibiotic for Treating Infections, Wounds, Diabetic Ulcers, Bed Sores, Burns, Rashes, Acne and many other skin conditions.
Market Data 
Markets 
AI
